TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an IgG4 Fc region instead of an IgG1 Fc. Their average twelve-month price target is $21.25, predicting that the stock has a possible upside of 76.64%. Amount of Analyst Coverage Trillium Therapeutics has received no research coverage in the past 90 days. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Olo, maker of restaurant-ordering tech, shares pop 28% in IPO, Dow trades fractionally higher, but Nasdaq slides ahead of Fed decision, Amazon jumps into health care, will provide telemedicine service to employers nationwide, Amid vaccine hurdles, EU battles to save summer vacations with COVID travel pass, Auto Parts Stocks Can Shift Higher, Analyst Says, Bond king Bill Gross says he made $10 million shorting GameStop, WHO urges countries to keep using AstraZeneca vaccine as ‘benefits outweigh risks’, COVID-19 vaccines get an endorsement from Trump, as daily U.S. deaths rise back above 1,000, Eviction filings increased after CDC issued nationwide moratorium, government report shows, TRIL will report 2020 earnings on 03/08/2022, TRIL will report Q4 2020 earnings on 05/07/2021. Evercore uses cookies to give you the best experience on our website. Tel: +1 857.412.7029, 2488 Dunwin Drive Finally, Evercore ISI assumed coverage on shares of Trillium Therapeutics in a research note on Monday, October 12th. Trillium Therapeutics (TRIL +2.3%) opens higher after Evercore ISI launches coverage at Outperform with a Street-high $28 price target, and a $60 bull case if Trillium … The firm issued an outperform rating and a $28.00 price target on the biotechnology company’s stock. Following recent promising clinical data updates and after raising over $300 million in 2020, the Company is now embarking on a substantial organizational scale-up to initiate a phase 2 program across a range of cancer indications. This browser is no longer supported at MarketWatch. They set an “outperform” rating and a $28.00 price target on the stock. Subscriber Agreement & Terms of Use, 5 Wall Street analysts have issued ratings and price targets for Trillium Therapeutics in the last 12 months. Find the latest analyst research for Trillium Therapeutics Inc. Common Shares (TRIL) at Nasdaq.com. Historical and current end-of-day data provided by FACTSET. 100 Cambridgepark Drive, Suite 510 View the latest ratings for TRIL. Institutions hold 68.87% of the Float. Forecasted annual earnings growth. Evercore ISI initiates coverage on Trillium Therapeutics (NASDAQ: TRIL) with a Outperform rating. Intraday Data provided by FACTSET and subject to terms of use. Trillium does not, by its reference above, imply its endorsement of or concurrence with such information, conclusions or recommendations. Cookie Notice (). Please note that any opinions, estimates or forecasts regarding Trillium's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Trillium or its management. To add more color to this target, the company’s high over the last year is $16.89 and the low is $0.24. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $21.25. According to TipRanks.com, Peaker is a 2-star analyst with an average return of -0.2% Trillium Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. For the best MarketWatch.com experience, please update to a modern browser. Analyst Coverage Trillium is followed by the analysts listed above. Institutions hold 68.87% of the Float. Please note that any opinions, estimates or forecasts regarding Trillium's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Trillium … How is Trillium Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts? Trillium Therapeutics has a 1-year low of $0.24 and a 1-year high of $7.97. The company’s shares closed last Monday at $5.22. Cambridge Office. A number of other equities research analysts have also recently commented on the stock. Something went wrong while loading Watchlist. The company’s shares closed last Monday at $3.92. Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Evercore ISI started coverage on shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) in a research report report published on Monday, Benzinga reports. Have Watchlists? By using this site you agree to the Tel: +1 416.595.0627 x232 Trillium Therapeutics Inc. analyst estimates, including TRIL earnings per share estimates and analyst recommendations. See Trillium Therapeutics Inc. (TRIL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Trillium is followed by the analysts listed above. The analyst commented, "We initiate coverage of Trillium Therapeutics with a Market Outperform rating and $10 price target, based on a discounted EPS and revenue multiple analysis. All quotes are in local exchange time. Several brokerages recently commented on TRIL. Summary. Cambridge Office. Shares of NASDAQ:TRIL opened at $6.78 on Tuesday. Copyright © 2021 MarketWatch, Inc. All rights reserved. Chief Financial Officer Bloom Burton cut Trillium Therapeutics from a "buy" rating to an "accumulate" rating … Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics (TRIL – Research Report) today. Trillium Therapeutics Inc. (TRIL) shares are trading at lower $14.97 and the avg recommendation for the stock is Strong Buy, while the current analyst price target stands at $11.02. According to analysts' consensus price target of C$25.00, Trillium Therapeutics has a forecasted upside of 67.3% from its current price of C$14.94. According to TipRanks.com , Peaker is a 4-star analyst with an average return of 4.4% and a 41.6% success rate. Visit a quote page and your recently viewed tickers will be displayed here. Find the latest Trillium Therapeutics Inc. (TRIL) stock quote, history, news and other vital information to help you with your stock trading and investing. There are currently no items in this Watchlist. USA 141 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with institutional investors hold 68.87% of the company’s shares. Trillium Therapeutics presently has a consensus rating of Buy and a consensus price target of $7.13. TTI-622 is Trillium’s second SIRPαFc fusion protein. TRIL.CA updated stock price target summary. Privacy Notice, and 141 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with institutional investors hold 68.87% of the company’s shares.
November 15, 2020 Astrology, Razorback Basketball Schedule 2020-21, Dark Void Zero Ds Rom, Guacamelee 100 Map, Just Gotta Be You, Hotel Palace Madrid Direccion, Art Classes For 15 Year Olds Near Me, Bobby Rush Obama,